J Biol Chem, Vol. 274, Issue 36, 25659-25667, September 3, 1999
Association of the Ras to Mitogen-activated Protein Kinase Signal
Transduction Pathway with Microfilaments
EVIDENCE FOR A p185neu-CONTAINING CELL SURFACE SIGNAL
TRANSDUCTION PARTICLE LINKING THE MITOGENIC PATHWAY TO A
MEMBRANE-MICROFILAMENT ASSOCIATION SITE*
Coralie A. Carothers
Carraway
§,
Maria E.
Carvajal
, and
Kermit L.
Carraway¶
From the Departments of
Biochemistry and Molecular
Biology, and ¶ Cell Biology and Anatomy, University of Miami
School of Medicine, Miami, Florida 33101
 |
ABSTRACT |
Microvilli of the aggressive 13762 ascites
mammary adenocarcinoma contain a large, microfilament-associated signal
transduction particle whose scaffolding is a stable glycoprotein
complex (Li, Y., Hua, F., Carraway, K. L., and Carraway, C. A. C. (1999) J. Biol. Chem. 274, 25651-25658)
associated with the growth factor receptor p185neu. The
receptor is constitutively tyrosine-phosphorylated in the cells and
microvilli, predicting that it should recruit mitogenic pathway
components to this membrane-microfilament interaction site.
Immunoprecipitation of cell lysates with anti-phosphotyrosine and
immunoblotting showed phosphorylated forms of the mitogenic pathway
proteins Shc and MAPK in addition to p185neu, suggesting that
the Ras to MAPK mitogenic pathway is activated. Immunoblotting of
p185neu-containing microvillar fractions revealed the presence
in each of stably associated Shc, Grb-2, Sos, Ras, Raf,
mitogen-activated protein kinase kinase, and mitogen-activated
protein kinase/extracellular signal-regulated kinase, as well
as the transcription factor-phosphorylating kinase Rsk. All of these
pathway components co-immunoprecipitated with p185neu from
cleared lysates of microvilli solubilized under
microfilament-depolymerizing conditions. The recruitment of
constitutively phosphorylated p185neu and the activated
mitogenic pathway proteins to this membrane-microfilament interaction
site provides a physical model for integrating the assembly of the
mitogenic pathway with the transmission of growth factor signal to the
cytoskeleton. This linkage is probably a requisite step in the global
cytoskeleton remodeling accompanying mitogenesis.
 |
INTRODUCTION |
Growth factors trigger both mitogenesis and changes in cell
morphology and microfilament organization (1). Since both of these
effects result from the binding of the factors to a single type of
receptor, their pathways must somehow be integrated. One suggestion for
this integration is that the receptors and components of the signaling
pathways are localized to sites where microfilaments interact with
membranes (2). The EGF1
receptor (3) and the EGF receptor family member p185neu
(ErbB2/HER2) (4) have been shown to be associated with microfilaments. EGF receptor binds directly to actin through a motif similar to the
actin-binding motif of profilin (5). The mechanism for the association
of p185neu/ErbB2 with microfilaments is presently unclear.
Interestingly, p185neu/ErbB2, which has been implicated in
tumor cell metastasis, is proposed to play a role in the regulation of
cell structure and motility (6). The receptor is concentrated on
microvilli in SK-BR-3 breast cancer cells. Activation of its
phosphorylation leads to cell spreading, enlargement of microvilli,
formation of pseudopodia, and aggregation of the p185 at the plasma
membrane protrusions and pseudopodia (6). A specific role for
p185neu/ErbB2 in these microfilament-dependent
processes known to enhance metastatic capability of tumor cells was
shown in p185neu-overexpressing transfectants of NCI-H460 lung
carcinoma cells (7).
Binding of a ligand to its receptor tyrosine kinase at the cell surface
elicits numerous pleiotypic cellular changes culminating in cell
division. This single activation event must integrate and orchestrate
both temporally and spatially a multiplicity of pathways regulating
metabolism, macromolecule biosynthesis, cytoskeletal organization, cell
cycle, and cell division. An early consequence of ligand binding is a
stimulation of the normally low level of tyrosine kinase activity of
the receptor (8-10) and autophosphorylation of the receptor on its
cytoplasmic domain, commonly on more than one tyrosine residue (11).
Kinase activation triggers events at the plasma membrane cytoplasmic
surface that initiate early steps in the transduction of growth signal
to the cytoplasm and nucleus. These phosphorylated tyrosine residues
create binding sites for other signal transduction components such as
adaptor (linker) proteins, via sequence-specific SH2 domains (12-14).
As a consequence, several signaling pathway proteins are recruited from
the cytosol to the cytoplasmic surface of the plasma membrane, resulting in modulation of their functions. The autophosphorylation and
recruitment permits at least transient associations of signal transduction proteins into complexes, called signal transduction particles (15).
Studies of mitogenesis induced by binding of EGF or platelet-derived
growth factor to its receptor have described a putative common
mitogenic pathway (16-19) that culminates in the phosphorylation of
transcription factors. The key cellular elements are the activated receptor (8, 9, 11, 14, 15, 20, 21), the (proto)oncogene product Ras
(22-28), and the protein kinases of the MAP kinase cascade (16-18,
29-32). Two of the critical events in this pathway entail recruitment
of soluble cytoplasmic proteins to the plasma membrane. The first
involves activation of Ras by Sos. In this proposed mechanism, the
autophosphorylated receptor binds to an adaptor protein such as Grb2
via a phosphotyrosine linkage to an SH2 or a PTB domain (33-37). The
adaptor protein interacts via its Src homology 3 domain with a
proline-rich peptide on Sos (33), a nucleotide exchange factor that can
activate Ras (33-39). This mechanism thus couples the phosphorylated
growth factor receptor to the activation of the membrane-associated
signal transduction switch Ras. Activation of the growth factor
receptor results in localization of the cytosolic Grb2-Sos complex in
juxtaposition with membrane-associated Ras via binding of the complex
to a phosphorylated tyrosine residue on the activated receptor (24,
40-42). Grb2-Sos can also be recruited indirectly to activated
receptors via the adaptor protein Shc (43, 44).
The second event requiring membrane localization involves the
recruitment of Raf and the downstream members of the MAPK pathway by
activated Ras (45, 46). Activated Ras has been shown to bind Raf
(47-51), a serine/threonine kinase that can initiate the MAPK cascade
(16-18, 29-32). However, no direct activation of Raf by Ras has been
observed (49). Instead, an important function of Ras appears to be the
recruitment of Raf to the plasma membrane (45, 46), inducing its
association with the microfilamentous cytoskeleton (46) by a protein(s)
X (2) with concomitant activation. During this assembly, Raf becomes
activated via an incompletely understood mechanism (52, 53) mediated in
some cells by the 14-3-3 protein family (54, 55), resulting in the
activation of the MAPKs. In this cascade Raf can activate MAPKK, which
activates MAPK. MAPK can then phosphorylate transcription factors as
part of the mitogenic process (16-18, 56). These combined observations
suggest the assembly at least transiently of a large, multimeric
signaling complex or signal transduction particle (4, 15), which
contains many if not all of the components of this pathway.
The results cited above suggest that the formation of signaling
complexes at membrane-microfilament interaction sites may play
important roles in cellular responses to growth factors (57, 58).
Partial pathway complexes have been demonstrated in some instances,
although these complexes are often transient and difficult to
characterize. Stable complete complexes more amenable to
characterization would be expected in the case of cells that are
constitutively activated, such as many types of tumor cells. The MAT-C1
subline of the 13762 rat mammary adenocarcinoma provides substantial
advantages for the investigations of membrane-microfilament
interactions and their regulation (59). Its cell surface is covered
with abundant microvilli, which can be readily isolated in quantity by
a simple shearing and differential centrifugation procedure that does
not destroy the cells or disrupt the structural organization of the
microvilli (60, 61). These microvilli provide a highly purified plasma
membrane fraction with intact microfilament-membrane interactions.
Extraction and fractionation studies on the microvilli have indicated
that microfilaments are linked to the membrane via a high molecular
mass (>106 Da) complex, designated the transmembrane
complex (62). As isolated from microvillar membranes, this complex
contains actin, at least five glycoproteins (63, 93), and a 58-kDa
cytoplasmic protein, p58gag. The growth factor receptor
p185neu (ErbB2/HER2), the protein product of the neu
(proto)oncogene, is a component of the stably associated TMC
glycoprotein complex that forms the core of the TMC (see model in
preceding paper (93), Fig. 10). Thus, the TMC has properties that
strongly suggest that it is a microfilament-associated signal
transduction particle (4, 93). The STP-associated p58, which binds to
both phospholipids and to microfilaments in the manner of a capping
protein (64), has been implicated in stability of the cell surface
receptors of ascites sublines (65, 66), which are xenotransplantable into mice (67). Complete cDNA sequencing revealed that p58 is a
truncated retroviral Gag-like protein lacking its nucleic acid-binding sequence (68). From lysates of untreated ascites cells, several tyrosine-phosphorylated proteins, including p58gag, were
immunoprecipitated with anti-phosphotyrosine antibody (69). Phosphoamino acid analysis indicated that p58gag is
phosphorylated on both tyrosine and serine. The membrane skeletal protein may be a substrate for the tyrosine kinases p60src
and/or p120abl, which, along with the receptor kinase
p185neu, are components of the large signaling particle (69).
p58gag has PXXP-containing polyproline motifs, a
general feature of retroviral Gag proteins, and was shown to bind to
both p60src (70) and
p120Abl.2
The presence of the receptor, the cytoplasmic kinases, and in
situ-phosphorylated substrate proteins, along with the aggressive properties of these highly metastatic tumor cells, suggest that p185neu is constitutively phosphorylated and activated (69).
This hypothesis also predicts that the activated growth factor receptor
will recruit components of its signal transduction pathway(s). In the
present study, we have used fractionation and co-immunoprecipitation
approaches to investigate the presence of components of the Ras/MAPK
pathway associated with the TMC. The results of these studies provide additional evidence for the presence of a microfilament-linked signal
transduction particle at the cell surface in the microvilli of these
cells. Moreover, they suggest that the STP/TMC is a site for
association of the Ras-Raf-MAPK pathway components at the plasma
membrane and provide a physical mechanism by which the cytoskeleton and
mitogenic pathways can be coupled. To our knowledge, the isolation of a
microfilament-associated, growth factor receptor-containing signaling
complex containing all of the components of the mitogenic pathway has
not been reported.
 |
EXPERIMENTAL PROCEDURES |
Materials
Antibodies were obtained from the following sources: Oncogene
Research Products (Cambridge), p185neu/ErbB2 mouse monoclonal
Ab3, pan-Ras mouse monoclonal; Dako (Carpinteria), ErbB2 rabbit
anti-human polyclonal antibody; Transduction Laboratories (Lexington,
KY), Shc rabbit polyclonal antibody, Sos (1 and 2) rabbit polyclonal
antibody, MAPKK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinases 1 and 2) rabbit polyclonal antibody, Rsk mouse monoclonal antibody, and horseradish peroxidase-conjugated phosphotyrosine (PY20 recombinant); Upstate Biotechnology, Inc. (Lake
Placid, NY), Grb2/Sem5 rabbit polyclonal antibody, human Raf-1
polyclonal rabbit antibody; Zymed Laboratories Inc.
(South San Francisco, CA), mouse monoclonal anti-MAPK (extracellular signal-regulated kinases 1 and 2) antibody; Promega Biotech (Madison, WI), mouse and rabbit IgG. All other chemicals were reagent grade and
obtained from Sigma, unless specified otherwise.
Methods
Passaging of Ascites Tumor Cells and Preparation of Microvilli
and Microvillar Fractions--
Ascites cells of the MAT-C1 subline of
the 13762 rat mammary adenocarcinoma were passaged by weekly
intraperitoneal injections into rats (65). Cells were collected and
washed with PBS. Microvilli (60), a microfilament-containing membrane
preparation, were prepared as previously reported (60, 61). The cell
bodies, undisrupted by this procedure, were removed by centrifugation at 750 × g, and the morphologically intact microvilli
were harvested and washed with PBS at 45,000 × g for
20 min prior to fractionation.
Preparation of microvillar microfilament core, membrane, and
TMC-enriched fractions--
Microfilament cores, microvillar
membranes, and TMC-enriched microvillar fractions were prepared as
previously reported (61, 63, 64, 71, 72). Microfilament cores were
prepared by extraction of microvilli in an isotonic
microfilament-stabilizing buffer (TPK buffer; 0.5% Triton, 100 mM KCl, 2 mM MgCl2, 0.1 mM phenylmethylsulfonyl fluoride, and 20 mM
PIPES, pH 6.8) for 15 min and either differential centrifugation (61)
or phalloidin shift velocity sedimentation, a diagnostic procedure for
analysis of microfilament-associated proteins (71). Microvillar
membranes containing membrane-associated but not filamentous actin were prepared under microfilament-depolymerizing conditions (low ionic strength, pH 9.5) according to the previously reported procedure (61,
63, 70). After centrifugation at 10,000 × g to remove undissociated microfilaments, the membranes were harvested at 150,000 × g for 1.5 h. This preparation contained
few of the microfilament-associated proteins. A transmembrane
complex-enriched preparation was made by extraction of microvilli on
ice for 30 min in a microfilament-depolymerizing buffer (S buffer
(0.2% Triton X-100, 150 mM KCl, 2 mM
MgCl2, 0.2 mM ATP, 0.2 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, and 5 mM Tris, pH 7.6); Refs. 63 and 64) containing a protease inhibitor mixture. Low speed centrifugation removed undissociated filaments, and high speed centrifugation yielded a cytoskeletal TMC
(cTMC) preparation containing small amounts of microfilament-associated proteins such as
-actinin and ezrin (63, 64, 72). A more highly
purified transmembrane complex was prepared by nonionic detergent
solubilization of microvillar membranes, followed by fractionation by velocity sedimentation or gel filtration
(62).
Immunoprecipitation of Tyrosine-phosphorylated Proteins from
Whole Cell Lysates--
Washed intact cells were solubilized in either
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl,
1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM
Tris, pH 8.0; Ref. 74) or 2% SDS followed by the addition of the other
components of RIPA buffer to give the same final concentrations of RIPA
components. The extracts were centrifuged at 120 × g
for 4 min. To the supernatants was added 50 µl of agarose-conjugated
antibody to recombinant anti-phosphotyrosine pY20, and the mixtures
were incubated overnight at 4 °C with rocking. The immune complexes
were obtained by centrifugation of the beads at 120 × g for 4 min and washing twice with PBS containing 0.02%
Triton. The pellet was resuspended in 100 µl of 2× SDS
electrophoresis buffer and subjected to electrophoresis and blot transfer.
Distribution of Mitogenic Pathway Proteins between the Microvilli
and the Cell Body--
The relative amounts of mitogenic pathway
components in whole cells and in cell bodies remaining after shearing
of microvilli and isolated microvilli were assessed by densitometry
quantification from immunoblots. To estimate the amount of microvilli
isolated from a given number of MAT-C1 cells, the cells were labeled
in vivo with 20 µCi of [14C]glucosamine
(Amersham Pharmacia Biotech), according to our standard procedure for
labeling glycosylated (predominantly cell surface) proteins (63, 75).
Aliquots representing equal numbers of cells and cell bodies, obtained
by counting, were prepared for SDS-PAGE. The amount of microvilli
corresponding to that number of cells/cell bodies to be prepared for
SDS-PAGE was taken to be the difference of the glucosamine counts
between identical numbers of cell and cell bodies. After immunoblotting
with antibodies to mitogenic pathway proteins (p185neu, Shc,
Grb2, Sos, Ras, Raf-1, MAPKK, MAPK, and Rsk; described below) and
detection by chemiluminescence, the bands on the film were quantified
by densitometry using a Hewlett-Packard Scanjet IIA Bioscan.
Immunoprecipitations of Transmembrane Complex-containing Low
Speed Supernatants with Antibodies to p185neu/ErbB2, MAPK, and
Raf-1--
300 µl of microvilli were incubated on ice for 30 min in
a microfilament-depolymerizing buffer containing a protease inhibitor mixture (S buffer; Refs. 62 and 73). The lysate was centrifuged at
15,000 × g for 15 min at 4 °C, and the supernatant
enriched in a cytoskeletal transmembrane complex preparation (63, 64, 72) was used for immunoprecipitations with antibodies to c-Neu, Raf,
and MAPK. Mouse monoclonal anti-MAPK (extracellular signal-regulated kinases 1 and 2), mouse monoclonal anti-c-Neu, rabbit anti-human Raf-1,
and appropriate nonimmune control antisera were incubated with protein
A-agarose (Sigma). Approximately 800 µl of lysate supernatant was
added to each, and the mixtures were incubated overnight at 4 °C.
The pellets were obtained by centrifugation at 3000 rpm for 5 min and
washed three times with PBS.
Electrophoresis and Blotting Procedures--
SDS-PAGE was
performed on 8% Laemmli minigels. For lectin binding analyses or
immunoblotting, proteins were transferred to nitrocellulose membranes
and processed as described previously (4, 63). Concanavalin A
(ConA)/horseradish peroxidase (Sigma) was used at 50 µg/ml and
detected using the RenaissanceTM chemiluminescence assay
kit (NEN Life Science Products).
Immunoblot Detection of Mitogenic Pathway
Proteins--
Immunoblotting was performed using the following
primary antibodies (sources listed above) and dilutions (optimized for
each antibody for detection by chemiluminescence): p185neu
mouse monoclonal antibody (1:4000); ErbB2 rabbit polyclonal antibody (1:500); pan-Ras mouse monoclonal antibody (1:750); human Raf-1 polyclonal rabbit antibody (1:2500); MAPKK (mitogen-activated protein
kinase/kinase) rabbit polyclonal antibody (1:1500); MAPK (extracellular
signal-regulated kinases 1 and 2) (1:2500); Rsk mouse monoclonal
antibody (1:500); and horseradish peroxidase-conjugated phosphotyrosine
(PY20 recombinant) (1:1000). In all cases, the second antibody was
either mouse (for polyclonal) or rabbit (for rabbit monoclonal) IgG
(1:14,000). Immunoblotting was performed as described previously (63,
69). The replicas were incubated with primary antibody in
Tween/Tris-buffered sodium chloride (500 mM NaCl, 50 mM Tris, pH 8.0) containing 1% bovine serum albumin for
1 h and with horseradish peroxidase-conjugated antibodies to
rabbit or mouse immunoglobulin for 1 h. Blots were washed, and the
reactive bands were detected using the NEN Life Science Products
RenaissanceTM chemiluminescence detection kit
according to the manufacturer's instructions.
 |
RESULTS |
Constitutive Tyrosine Phosphorylation of p185neu and Other
MAT-C1 Proteins--
Observations from previous studies on the highly
proliferative and metastatic MAT-C1 cells predict that the mitogenic
pathway is constitutively activated. Several constitutively
phosphorylated substrate proteins for both tyrosine- and
serine/threonine-specific kinases have been identified, including the
membrane skeletal protein p58gag (69). A high
Mr protein in the 150-200-kDa range was
tyrosine-phosphorylated, suggesting that p185neu in the
MAT-C1 cells may be constitutively phosphorylated and therefore capable
of binding cytoplasmic signaling components having SH2 domains. This
question was addressed by immunoprecipitation of cell lysates with
anti-Tyr(P) and analysis of the immunoprecipitate by immunoblotting.
Our previous studies on MAT-C1 microvilli had indicated that preparing
cell lysates with nonionic detergent is completely inadequate for
solubilizing the large, stable complexes at the membrane-microfilament
interface (4, 62-64). Therefore, denaturing conditions were required
for the solubilization of TMC-containing fractions. MAT-C1 cell lysates
were prepared in two ways. The first employed RIPA buffer (74), which
was designed to dissociate complexes prior to immunoprecipitation. RIPA
did not completely dissociate the TMC (data not shown), and for this
reason SDS was routinely used to dissociate completely all
protein-protein interactions in the complex. The latter procedure also
denatures and destroys the activities of cellular enzymes, such as
phosphatases and proteases, which could alter the phosphorylated
proteins during the analyses. When diluted appropriately, the
SDS-solubilized material was amenable to immunoprecipitation and other
types of binding experiments (see preceding paper (93), in which
concanavalin-agarose is used to fractionate SDS-solubilized cell fractions).
To determine whether p185neu is the high
Mr protein, the anti-Tyr(P) immunoprecipitate
from the whole cells lysed with SDS was assayed by immunoblot with
anti-p185neu. Fig. 1 shows the
presence of p185neu in the immunoprecipitates. Exhaustive
immunoprecipitation of cell lysates with anti-phosphotyrosine-agarose,
followed by immunoblotting of the final supernatant with either the
monoclonal or polyclonal anti-ErbB2, revealed that >95% of the
p185neu in the intact, untreated cells is phosphorylated (data
not shown). The phosphorylated receptor would be expected to recruit
SH2 domain-containing proteins to the plasma membrane to initiate the
assembly of a signaling complex containing components of the
mitogenic pathway. One mechanism for the recruitment involves the
adaptor protein Shc (43, 44), which can be phosphorylated on tyrosine.
Analysis of the anti-phosphotyrosine immunoprecipitates by
immunoblotting with anti-Shc demonstrated that it is phosphorylated in
the ascites cells (Fig. 1B). A major indicator of mitogenic
activation is the dual phosphorylation of MAPK on both tyrosine and
threonine (16-18, 29-32). Tyrosine phosphorylation of MAPK was
demonstrated by the presence of the MAPK in the anti-phosphotyrosine
immunoprecipitates (Fig. 1B). The presence of activated MAPK
was also shown by immunoblotting with antibody to activated
MAPK.3

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 1.
Anti-Tyr(P) immunoprecipitation of
solubilized whole cells. Washed cells were lysed in RIPA buffer
and subjected to immunoprecipitation with
anti-Tyr(P)-agarose, as described under "Methods." The pellets
were analyzed by SDS-PAGE and electrotransfer to
nitrocellulose for immunoblotting with anti-Tyr(P) and
anti-ErbB2, -Shc, and -MAPK antibodies. MF,
microfilament; IP, immunoprecipitation.
|
|
Recruitment of Signaling Components to the Plasma Membrane--
In
previous studies we showed that the receptor tyrosine kinase
p185neu is associated with a high Mr
glycoprotein complex (63) linked to microfilaments in microvilli from
13762 ascites rat mammary adenocarcinoma cells (Ref. 4 and preceding
paper (Ref. 93)). We have proposed that the TMC-p185 complex can act as
a signal transduction particle that can recruit signal transduction
components from the cytoplasm to the membrane-microfilament interface
as part of the cell activation process. These results led us to predict that the glycoprotein complex forms the core of a signal transduction particle which can organize and integrate signaling pathways at the
membrane-microfilament interface (2, 58). As demonstrated above, these
highly proliferative cells have constitutively phosphorylated p185neu/ErbB2. These findings would predict that the
tyrosine-phosphorylated receptor can recruit signal transduction
components containing SH2 domains from the cytoplasm to the membrane.
To analyze association of mitogenic pathway components with the plasma
membrane, we isolated microvilli (60, 61), which comprise over 80% of
the plasma membrane of these cells, by shearing them from the ascites
cells, leaving intact cell bodies (61). A direct quantitative
comparison is not feasible because of losses in yield during
preparation. In order to compare microvilli and cell body preparations
and correct for losses of microvilli during their preparation, the ascites cells were metabolically labeled with glucosamine. To obtain an
estimate of the amount of purified microvilli obtained from a given
number of cells, we used as starting material ascites cells labeled
metabolically with glucosamine (63, 75). In previous studies, we have
shown that about 90% of the glucosamine is incorporated into an
abundant cell surface glycoprotein complex, the sialomucin complex
(75), serving as a quantifiable marker for the plasma membrane. Since
this complex is distributed throughout the cell surface, on both the
microvilli and nonvillous areas of the plasma membrane, glucosamine
labeling provides a minimal estimate of the plasma membrane content of
the cells.
For these experiments, cells were labeled with glucosamine in
vivo (63) and then sheared to remove microvilli. Cell bodies were
isolated by centrifugation. For quantitation, we analyzed by SDS-PAGE
equal numbers of intact cells and cell bodies, determined by cell
counting. To determine the amount of microvilli for analysis, aliquots
of cells and cell bodies were assayed for radioactivity by
scintillation counting. The difference in label between the cells and
cell bodies represents the amount of label in the microvilli. By
loading that amount of microvillar fraction radioactivity onto SDS-PAGE, we can analyze equivalent amounts of cells, cell bodies, and
microvilli and eliminate problems from loss of microvilli during the
procedure. This method provides a minimal estimate for microvilli,
since the membrane of the cell bodies retain a portion of the
microvilli (61). According to our glucosamine measurements, the amount
of membrane on the sheared cells is approximately 20% of the total.
The SDS-PAGE gels were then assayed by immunoblotting with antibodies
to selected components of the Ras/MAPK pathway to evaluate their
recruitment to the plasma membrane from the cytoplasm.
Results from these immunoblots are shown in Fig.
2. Qualitatively, it is clear that there
are similar amounts of each of the signaling components in microvilli
and in the cell bodies, which retain some plasma membrane. This
observation was verified quantitatively by densitometric scanning of
the immunoblot bands, as shown in Table I
for a typical experiment. Since the microvilli contain little
cytoplasmic material (61) and the cell bodies contain a fraction of the
membrane, these results suggest that the signaling proteins are to a
significant extent associated with the microvilli (pure plasma
membrane) in these cells. Regardless of the exact quantification, these
results clearly demonstrate that substantial amounts of the components
of the Ras/MAPK signaling pathway are associated with the plasma
membrane, consistent with our hypothesis that they are recruited to the
p185neu-containing signaling particle at the
membrane-microfilament interface.

View larger version (73K):
[in this window]
[in a new window]
|
Fig. 2.
Distribution of pathway components between
tumor cell bodies and microvilli. MAT-C1 cells were metabolically
labeled in vivo with glucosamine and sheared to remove
microvilli. Cell bodies and microvilli were isolated by differential
centrifugation. Intact cells and cell bodies were counted and analyzed
for glucosamine label by scintillation counting. For SDS-PAGE, equal
numbers of cells and cell bodies were solubilized and loaded onto the
gels. The sample of microvilli loaded was equivalent to the difference
in radioactivity between the cells and cell bodies. The SDS-PAGE gels
were analyzed by immunoblotting with the appropriate antibodies.
|
|
As shown in Table I, minimally half of each of the Ras to MAPK central
pathway components are associated with the microvilli. This is expected
for Ras, which is targeted to the membrane component by prenylation of
its carboxyl terminus (76). On the other hand, Grb2-Sos complex, Raf,
MAPKK, and MAPK are cytoplasmic or nuclear until recruited to the
membrane by an activation event (overviewed in Ref. 2). The presence of
all of these normally intracellular proteins at the
membrane-microfilament interface provides further evidence for the
constitutive activation of the ascites tumor cells. Interestingly,
p90rsk, a MAP kinase substrate found in the cytoplasm and the
nucleus in both activated and unactivated cells (77), was present at the membrane in similar proportions to the other pathway proteins.
Association of Signal Transduction Pathway Components with
STP/TMC-containing Microvillar Particulate Fractions--
Our
hypothesis that components of the Ras/MAPK pathway are associated with
the membrane-microfilament interface was first tested by fractionating
the microvilli to determine whether the signaling components
co-fractionate with the p185neu-containing STP. Extraction
under mild conditions (isotonic buffer, pH 6.8) and differential
centrifugation yields a relatively intact microfilament core that
sediments at low speed (61, 72). Centrifugation of the supernatant from
this sedimentation at 100 kg yields the TMC containing actin but no
microfilaments (61, 72). A microfilament-depleted high speed pellet
called the cytoskeletal TMC, which is enriched in membrane skeletal
proteins (63, 64, 72), was made by Triton extraction of microvilli at
pH 9.5 and low ionic strength to depolymerize microfilaments.
Immunoblot analyses of the particulate microvillar fractions revealed
that Ras, Grb2, Sos, Raf, MAPKK, and MAPK were associated with the
p185neu-containing TMC fractions, including the cTMC (Fig.
3). Interestingly, there is some
variation in the fraction of the different components that remain
associated with the microfilaments. As shown previously, p185neu is largely associated with the microfilament core when
extraction is performed under mild conditions (4). Moreover, Grb2 is
stably associated with the core, as expected for linkage via an
SH2-tyrosine phosphate interaction. Interestingly, MAPK associated
preferentially with the microfilament-containing low speed pellet,
suggesting a more immediate association of the terminal Ras-to-MAPK
pathway component with a microfilament-associated protein. Most of the other components are less stably associated. The stringency of the
extraction conditions for generating the cTMC suggests a stable complex
of these components with the glycoprotein complex that forms the core
of the TMC, although the interactions involved in this complex are
undefined.

View larger version (97K):
[in this window]
[in a new window]
|
Fig. 3.
Association of mitogenic pathway components
with STP-containing microvillar microfilament core and TMC
fractions. Microvilli and fractions prepared as described
previously (63) were analyzed by SDS-PAGE and electrotransfer onto
nitrocellulose for immunoblotting using antibodies against mitogenic
pathway components. MV, microvilli; MF,
microfilament.
|
|
A noteworthy observation is that the MAPK substrate p90rsk,
found in the previous experiment to be recruited in significant amount to the microvilli at the membrane, is also stably associated with the
p185neu-containing complex in the particulate microvillar
fractions. The interaction of Rsk with the membrane skeletal complex
appears stable, since this kinase is abundant despite the
stringent conditions for cTMC preparation.
While the large, stable signaling complex contains all of the Raf to
MAPK to Rsk mitogenic pathway components, a number of signal
transduction proteins, both receptor and nonreceptor types, were not
associated. Table II shows that Ras
GTPase-activating protein (Ras GAP), the insulin receptor, and
transforming growth factor
receptor types I and II, although
present in the microvilli, were found largely in the complex-depleted
soluble fraction; EGF receptor is not expressed in the ascites cells
(4).
Velocity Sedimentation Analysis of the Association of Signal
Transduction Components with Microfilament Core--
To circumvent
potential co-sedimentation artifacts, which may erroneously imply the
existence of proteins in a specific microfilament-associated complex,
we have developed the phalloidin shift analyses of microvilli (71).
Phalloidin binds specifically to microfilaments and stabilizes them to
dissociation. A comparison of the migration on velocity sedimentation
of the microfilament fractions of phalloidin-treated and -untreated
microvillar extracts shows a shift of the stabilized filaments and any
proteins in that complex farther into the gradient. Fig.
4 shows the distribution of the mitogenic
pathway proteins in the gradient fractions, with both the large STP/TMC
at the bottom and in soluble fractions in the upper portion. As
expected, the amount of the components associated with microfilaments
is less on the gradients than in the sedimented pellets because of the
time required for analysis by gradient centrifugation. Interestingly, the presence of Raf in middle fractions suggests that it is being released during centrifugation, suggesting a more direct association with microfilaments than other components. The fact that
microfilament-unassociated forms of other components also do not
migrate as suggested by their molecular sizes (for example, see Rsk)
suggests that they may be present in smaller complexes released from
the microfilaments. Analyses of these putative complexes may help to
resolve questions about molecular interactions in associations of the
signaling proteins with the microfilaments.

View larger version (96K):
[in this window]
[in a new window]
|
Fig. 4.
Distribution of mitogenic pathway proteins by
velocity sedimentation analysis of microvilli lysed in
Triton-containing microfilament-dissociating buffer. Microvilli
extracted in low ionic strength, high pH buffer containing Triton were
subjected to velocity sedimentation analysis (62). The gradient
fractions were analyzed by immunoblotting with antibodies to mitogenic
pathway components and to TMC-gp65 and TMC-gp55.
|
|
Co-immunoprecipitation of p185neu and Mitogenic Pathway
Proteins from STP/TMC-enriched Microvillar Extract--
The major
problem in characterizing interactions between specific proteins in the
microfilament-associated STP has been the generation of small enough
complexes. Extensive cross-linking and stabilization of microfilaments
with proteins such as
-actinin (60) prevent complete
depolymerization under traditional actin-depolymerizing conditions
(62). Further, the large size of the stably associated receptor-containing TMC/STP-glycoprotein complex (93) with which the
signaling proteins associate precludes simple immunoprecipitation of
microvillar lysates. A smaller complex was generated by lysing microvilli with S buffer, the depolymerization buffer used in the
preparation of the TMC (62), and clearing the lysate of undepolymerized
microfilaments and associated proteins by centrifugation at low
speed. The supernatant, which retains a portion of the STP released
from microfilaments, was subjected to immunoprecipitation with
antibodies to p185neu/ErbB2. As a negative control,
immunoprecipitations were performed with antibodies to EGF receptor,
which is not expressed in these cells (4). All of the proteins of the
mitogenic pathway were co-immunoprecipitated with
p185neu/ErbB2, as shown in Fig.
5. Immunoprecipitation with antibodies to
Raf and MAPK, as well as any of the other components, gave essentially
identical results (data not shown). The observation that the components
immunoprecipitated were the same regardless of the antibody used
indicates that different complexes containing one component were not
being co-immunoprecipitated with its specific antibody.

View larger version (74K):
[in this window]
[in a new window]
|
Fig. 5.
Co-immunoprecipitation of p185neu and
signaling proteins by anti-p185 immunoprecipitation of TMC-enriched
soluble fraction of microvilli extracted in actin-depolymerizing buffer
containing Triton. Microvilli were extracted in the
microfilament-dissociating buffer used and subjected to velocity
sedimentation analysis, as previously reported for the original
isolation of the TMC (62). SDS-PAGE was performed on the fractions, and
immunoblots were analyzed with antibodies to mitogenic pathway
proteins.
|
|
 |
DISCUSSION |
Mitogenesis entails a complex series of pleiotypic events,
requiring not only the transmission of signals to the nucleus, but also
massive remodeling of the cell cytoskeleton in preparation for and
during cell division. Although considerable progress has been made in
understanding the pathways involved in transmitting growth factor
signals to the nucleus to activate transcription factors, much less is
known about the regulation of the organization and reorganization of
the cytoskeleton. In particular, little is known about how the pathways
integrating the signal to the nucleus and to the cytoskeleton are
physically organized. A developing paradigm for eliciting pleiotypic
cellular responses to diverse ligands for plasma membrane receptors is
that transmission of the signal to several pathways involves
recruitment of the components of the pathways to sites of interaction
of the plasma membrane with the cytoskeleton (discussed at length in
Ref. 58). These membrane-microfilament interaction sites in the plasma
membrane are often involved in both establishing and stabilizing cell
morphology (2, 58) and have been shown to be enriched in tyrosine
kinases and their substrates, which have been implicated in mitogenesis.
Microvilli of 13762 rat mammary adenocarcinoma cells provide a useful
model for investigating membrane-microfilament interactions. Fractionation studies on the microvilli have shown that a
p185neu/ErbB2-containing, high Mr
glycoprotein complex, the TMC-gp complex, is associated with
microfilaments (4, 63). The glycoprotein complex has been isolated as a
transmembrane complex with actin and cytoplasmic p58gag (62)
or, under more stringent conditions (1 M KCl, pH 9.5), as a
complex of glycoproteins (TMC-gp complex; gp55, gp65, gp80, gp110, and
gp120 (63)). Under denaturing conditions it could be purified free of
cytoplasmic proteins and reconstituted into the large glycoprotein
complex (93). In that study, overlay analyses with actin showed that at
least one of the glycoproteins interacts directly with actin.
Furthermore, fractionation (4) and reconstitution studies (93) showed
that the tyrosine receptor kinase p185neu/ErbB2 associates
directly with the TMC-gp. The presence of the growth factor receptor
kinase at a site involved in regulating microfilament and cell surface
dynamics suggests that, like integrin-containing adhesion plaques (79)
and cadherin-containing adherens junctions (80), the glycoprotein
complex is a membrane-microfilament interaction site, which transduces
signal to microfilaments to regulate cell morphology. Hence, this site
provides a physical scaffolding for the integration of growth factor
signals to the mitogenic pathway and to the cytoskeleton.
An additional important feature of these highly proliferative tumor
cells is that their mitogenesis pathway appears to be constitutively
stimulated. MAT-C1 microvilli show a high level of tyrosine kinase
activity and several specific tyrosine-phosphorylated proteins (69). At
least three tyrosine kinases co-purify with the STP,
p185neu/ErbB2 (4), p60src, and p120abl (69). Of
these, at least one, p185neu/ErbB2, is activated, based upon
its immunoprecipitation from lysates of the MAT-C1 cells with
anti-phosphotyrosine (Fig. 1). Further, MAP kinase is activated, as
shown in two types of experiments: 1) abolition of its activity by
dephosphorylation of immunoprecipitated MAP kinase) and 2)
immunoblotting with anti-activated
MAPK.4 The phosphorylation of
p185neu/ErbB2 should permit it to recruit SH2-containing
factors from the cytoplasm, initiating the formation of a signaling
particle. Using both co-sedimentation and co-immunoprecipitation, we
demonstrated the association of Shc, Grb-2, and Sos with the TMC. This
was not surprising, since they are required to initiate the mitogenic pathway by activating membrane-associated Ras. However, blotting for
the other members of the MAP kinase cascade (Raf, MAP kinase kinase,
and MAP kinase) showed that the complete pathway, as well as
p90rsk, is stably assembled in the STP/TMC (Fig.
6). Although the complex is large
(>2 × 106 Da; Refs. 62 and 63), the assembly of the
complete mitogenic pathway complex was not necessarily expected. This
point emphasizes a very important caveat in analyzing signaling
complexes; multiplicity of components is recognized only if appropriate
assays are used. Size analyses of complexes, as reported for the TMC
(62), the TMC-gp complex (63, 93), and a complex of Raf with the
molecular chaperones hsp90 and p50 (81), provide valuable information on the nature of the complexes. The size of the TMC indicated that
individual components were present in multiple copies and/or that
multiple components were present.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 6.
Model of the TMC/STP as a
microfilament-associated mitogenic pathway complex, a site for
cross-talk between the Ras MAPK pathway and
the cytoskeleton.
|
|
The presence of the signaling components in STP-enriched fractions
prepared under relatively harsh conditions (e.g. high pH/low ionic strength used in the preparation of cTMC (63, 64, 72)) suggests
stable interactions among components in the complex. Indeed, the fact
that RIPA buffer, developed for dissociation of proteins prior to
immunoprecipitation (74), is ineffective in completely solubilizing the
various forms of the STP/TMC indicates an unusual degree of stability
of protein-protein interactions in the complex. These observations
necessitate a second caveat; incomplete dissociation can lead to an
erroneous inference of direct interaction if more than two proteins are
present in the complex. This problem becomes particularly difficult
when dealing with large, stable complexes, such as those frequently
found at membrane-microfilament interaction sites.
The isolation of components of the mitogenic pathway with the STP/TMC
was facilitated by the fact that the p185neu/ErbB2 in the
highly proliferative ascites cells is constitutively activated.
Essentially all of the MAT-C1 cell p185neu/ErbB2 was shown to
be tyrosine-phosphorylated, providing binding sites for SH2
domain-containing proteins. One possible mechanism for the activation
is through mutation of specific components of the pathway, such as Ras
or Raf; we have no evidence for such a mutation(s), whose activation
mechanisms, on any account, would bypass the growth factor receptor. An
alternative for activation of the receptor and the pathway is via
autocrine growth factors, since many tumors are known to produce these
factors. Of particular interest is the fact that the 13762 ascites
cells contain a specific activator of the p185neu/ErbB2 (82).
This modulator ASGP-2 is an integral membrane glycoprotein having two
EGF-like domains (83), which associates with p185neu/ErbB2
specifically, stimulating its phosphorylation and tyrosine kinase
activity (82). Further, ASGP-2 potentiates the level of
NDF/heregulin-activated phosphorylation of ErbB2 and ErbB3 (82). Thus,
we propose that ASGP-2, which binds to ErbB2 in the absence of the
other ErbB receptors, can activate ErbB2 as well as modulating
signaling through the ErbB2/ErbB3 heterodimer. In previous studies, the
purported ligand was characterized as the transmembrane subunit ASGP-2
(83) of the 13762 ascites cell sialomucin complex (75). ASGP-2 appears
to be an epithelial specific protein found in lung (84), uterus (85),
colon (86), and lactating but not virgin mammary gland in the rat (87). A fraction of ASGP-2 associates stably with the TMC (88), presumably through an interaction with p185neu/ErbB2, since the purported
ligand can be co-immunoprecipitated with p185neu/ErbB2 from
solubilized ascites cell membranes under conditions (pH 9.5, low ionic
strength) in which a fraction of the p185neu/ErbB2-containing
complex becomes dissociated from the microfilament-associated TMC
(82).
Regardless of the mechanism of constitutive activation, it is clear
that the STP/TMC is a major site for cross-talk in the 13762 ascites
tumor cells. Minimally, mitogenic signaling through p185neu/ErbB2 is transduced to the microfilament-based
cytoskeleton in the cell surface microvilli, which in turn must be
linked to the intracellular cytoskeleton in the intact cell. It is
likely that this receptor complex mediates cross-talk with yet other
pathways, since it also contains p60src, p120abl (69),
the p85 subunit of PI-3-kinase, phospholipase C
, and modulators of
the mitogenic pathway, including some isoforms of protein kinase C and
specific phosphatases.5
Interestingly, the insulin receptor, transforming growth factor
receptors I and II, and Ras GAP, although present in the microvilli, are excluded from the complex.
A plethora of questions remain on the organization and functions of the
signaling complex. The size and stability of the multimeric complex
precludes a simple answer to the question of molecular interactions
among complex components. The first step is presumably recruitment of
signaling proteins to the phosphorylated receptor via SH2 or PTB
domains. It is not completely clear at present which signaling proteins
bind directly to the activated ErbB2 receptor. The Grb2 SH2 domain has
been reported to have a consensus binding sequence for
p185neu/ErbB2 (89), and this adaptor protein binds in
situ to ErbB2 (90). In addition, Shc can bind in vitro
to ErbB2 via its PTB domain (91). Either or both of these adaptors are
candidates for binding to phosphorylated ErbB2 and recruitment of Ras
to the STP/TMC. From that point, a plausible assembly pathway would involve association of Ras with Raf, of Raf with MAPKK, and of MAPKK to
MAPK, interactions that have been shown to occur in mitogenic complexes.
The somewhat surprising observation was the stable association of
p90rsk with membrane-microfilament interaction site. However,
Rsk has been shown to bind to MAPK and has been reported to localize to the cell periphery (92), although the mechanism or cellular significance is not clear. Our data suggest a potential mechanism involving linkage of a signal transduction particle to microfilaments and implicate p90rsk at least indirectly in linking the
mitogenic pathway to morphological alterations after a signaling event.
Current knowledge is minimal in the important area of mechanisms for
the temporal and spatial regulation of the localization and
relocalization of mitogenic pathway components in signaling (discussed
in Chapter 8 of Ref. 58). The significance of the nuclear transport of
cytoplasmic pathway proteins on activation is intuitive. Not so easily
understood is the significance of the presence in both the cytoplasm
and the nucleus of pathway components such as MAPK, with the kinase at
both locations becoming activated. A second poorly understood area is
the significance, regulation, and mechanisms for cytoplasmic sequestration and for relocalization of nuclear export motif-containing proteins such as mitogen-activated protein kinase/extracellular signal-regulated kinase into and then back out of the nucleus after
activation. Finally, the appearance of nuclearly localized signaling
proteins at the plasma membrane has from time to time been reported,
yet the mechanisms for membrane localization have not been described
nor have insights into the cellular function of this localization been
proffered. These important regulatory questions are a major challenge
and will predictably involve, in many cases, the cytoskeleton and its
associations with the plasma membrane.
Our results indicate that the TMC contains all of the elements
necessary for integrating the regulation of microfilament organization and the transmission of the mitogenic signal to MAP kinase and Rsk and
thus to the nucleus. These elements include sites of interaction with
microfilaments, the receptor tyrosine kinase p185neu, and the
MAP kinase cascade, possibly through binding of Raf to the TMC. Since
MAP kinase in the microvilli is phosphorylated and active, the TMC may
also contain a component that activates Raf as the first step in
stimulating the MAP kinase cascade. Studies are under way to define
these specific components of the TMC.
Integration of proliferation and cytoskeletal signals suggests a common
site. We have proposed that the dynamics of microfilaments in the
MAT-C1 cells is regulated at the site of the microfilament-membrane interaction, because p58gag at that site appears to stabilize
the microvilli, presumably by stabilizing the TMC-gp interactions.
Thus, the STP includes both the scaffold for the mitogenic pathway
components and a site for regulating microfilament dynamics, as
required for integration. The study of the regulation of microfilament
dynamics at this site is difficult in these cells, because of the
presence of the stabilizing factor p58gag. However, other MAT
sublines lacking p58 (62) and having dynamic microvilli (65, 66) may be
amenable to such studies.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants GM 33795 and CA 72074.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Biology (R-629), University of Miami School of Medicine,
Miami, FL 33101. Tel.: 305-243-5759; Fax: 305-243-4431; E-mail:
ccarrawa@mednet.med.miami.edu.
2
J. Huang, S. Price-Schiavi, R. Van Etten,
B. J. Mayer, and C. A. C. Carraway, manuscript in preparation.
3
M. Carvajal, unpublished observation.
4
D. Lorenzo and M. Carvajal, unpublished observations.
5
M. Carvajal and I. Lovinescu, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
EGF, epidermal
growth factor;
cTMC, cytoskeletal transmembrane complex;
MAP, mitogen-activated protein;
MAPK, MAP kinase;
MAPKK, MAPK kinase;
PBS, phosphate-buffered saline (Dulbecco's, no Ca2+);
PIPES, piperazine-N,N'-bis(2-ethanesulfonic acid);
RIPA, radioimmunoprecipitation assay;
PAGE, polyacrylamide gel
electrophoresis;
SH2, Src homology 2;
STP, signal transduction
particle;
TMC, transmembrane complex;
TMC-gp, transmembrane complex
glycoprotein.
 |
REFERENCES |
| 1.
|
Bretscher, A.
(1991)
Annu. Rev. Cell Biol.
7,
337-374[CrossRef]
|
| 2.
|
Carraway, K. L.,
and Carraway, C. A. C.
(1995)
BioEssays
17,
171-175[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Wiegant, F. A. C.,
Blok, F. J.,
Defize, L. H. K.,
Linnemans, W. A. M.,
Verkleij, A. J.,
and Boonstra, J.
(1986)
J. Cell Biol.
103,
87-94[Abstract/Free Full Text]
|
| 4.
|
Carraway, C. A. C.,
Carvajal, M. E.,
Li, Y.,
and Carraway, K. L.
(1993)
J. Biol. Chem.
268,
5582-5587[Abstract/Free Full Text]
|
| 5.
|
den Hartigh, J. C.,
van Bergen en Henegouwen, P. M. P.,
Verkleij, A. J.,
and Boonstra, J.
(1992)
J. Cell Biol.
119,
349-355[Abstract/Free Full Text]
|
| 6.
|
De Potter, C. R.,
and Quatacker, J.
(1993)
J. Clin. Exp. Metastasis
11,
453-461
|
| 7.
|
Yu, D.,
Wang, S. S.,
Dulski, K. M.,
Tsai, C. M.,
Nicolson, G. L.,
and Hung, M. C.
(1994)
Cancer Res.
54,
3260-3266[Abstract/Free Full Text]
|
| 8.
|
Fantl, W. J.,
Johnson, D. E.,
and Williams, L. T.
(1993)
Annu. Rev. Biochem.
62,
453-481[Medline]
[Order article via Infotrieve]
|
| 9.
|
Lemmon, M. A.,
and Schlessinger, J.
(1994)
Trends Biochem. Sci.
19,
459-463[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
van der Geer, P.,
and Hunter, T.
(1994)
Annu. Rev. Cell Biol.
10,
251-337[CrossRef]
|
| 11.
|
Panayotou, G.,
and Waterfield, M. D.
(1993)
BioEssays
15,
171-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Pawson, T.,
and Gish, G. D.
(1992)
Cell
71,
359-362[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Birge, R. B.,
and Hanafusa, H.
(1993)
Science
262,
1522-1524[Free Full Text]
|
| 14.
|
Feller, S. M.,
Ren, R.,
Hanafusa, H.,
and Baltimore, D.
(1994)
Trends Biochem. Sci.
19,
453-458[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Ullrich, A.,
and Schlessinger, J.
(1990)
Cell
61,
203-212[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Blenis, J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5889-5892[Abstract/Free Full Text]
|
| 17.
|
Davis, R. J.
(1993)
J. Biol. Chem.
268,
14553-14556[Free Full Text]
|
| 18.
|
Ruderman, J. V.
(1993)
Curr. Opin. Cell Biol.
5,
207-213[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Maruta, H.,
and Burgess, A. W.
(1994)
BioEssays
16,
489-496[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Yarden, Y.,
and Ullrich, A.
(1988)
Annu. Rev. Biochem.
57,
443-478[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Cadena, D. L.,
and Gill, G. N.
(1992)
FASEB J.
6,
2332-2337[Abstract]
|
| 22.
|
Bollag, G.,
and McCormick, F.
(1991)
Annu. Rev. Cell Biol.
7,
601-632[CrossRef]
|
| 23.
|
Haubruck, H.,
and McCormick, F.
(1991)
Biochim. Biophys. Acta
1072,
215-229[Medline]
[Order article via Infotrieve]
|
| 24.
|
Downward, J.
(1992)
BioEssays
14,
177-184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Satoh, T.,
Nakafuku, M.,
and Kaziro, Y.
(1992)
J. Biol. Chem.
267,
24149-24152[Free Full Text]
|
| 26.
|
Marshall, M. S.
(1993)
Trends Biochem. Sci.
18,
250-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Lowy, D. R.,
and Willumsen, B. M.
(1993)
Annu. Rev. Biochem.
62,
851-891[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Polakis, P.,
and McCormick, F.
(1993)
J. Biol. Chem.
268,
9157-9160[Abstract/Free Full Text]
|
| 29.
|
Pelech, S. L.,
and Sanghera, J. S.
(1992)
Science
257,
1355-1356[Free Full Text]
|
| 30.
|
Thomas, G.
(1992)
Cell
68,
3-6[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Leevers, S. J.,
and Marshall, C. J.
(1992)
Trends Cell Biol.
2,
283-286
[CrossRef][Medline]
[Order article via Infotrieve] |
| 32.
|
Nishida, E.,
and Gotoh, Y.
(1993)
Trends Biochem. Sci.
18,
128-131[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Egan, S. E.,
Giddings, B. W.,
Brooks, M. W.,
Buday, L.,
Sizeland, A. M.,
and Weinberg, R. A.
(1993)
Nature
363,
45-51[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Rozakis-Adcock, M.,
Fernley, R.,
Wade, J.,
Pawson, T.,
and Bowtell, D.
(1993)
Nature
363,
83-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Li, N.,
Batzer, A.,
Daly, R.,
Yajnik, V.,
Skolnik, E.,
Chardin, P.,
Bar-Sagi, D.,
Margolis, B.,
and Schlessinger, J.
(1993)
Nature
363,
85-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Kavanaugh, W. M.,
and Williams, L. T.
(1994)
Science
266,
1862-1865[Abstract/Free Full Text]
|
| 37.
|
Buday, L.,
and Downward, J.
(1993)
Cell
73,
611-620[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Simon, M. A.,
Bowtell, D. D. L.,
Dodson, G. S.,
Laverty, T. R.,
and Rubin, G. M.
(1991)
Cell
67,
701-716[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Simon, M. A.,
Dodson, G. S.,
and Rubin, G. M.
(1993)
Cell
73,
169-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Olivier, J. P.,
Raabe, T.,
Henkemeyer, M.,
Dickson, B.,
Mbamalu, G.,
Margolis, B.,
Schlessinger, J.,
and Hafen, E.
(1993)
Cell
73,
179-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Chardin, P.,
Camonis, J. H.,
Gale, N. W.,
van Aelst, L.,
Schlessinger, J.,
Wigler, M. H.,
and Bar-Sagi, D.
(1993)
Science
260,
1338-1343[Abstract/Free Full Text]
|
| 42.
|
Downward, J.
(1996)
Cancer Surv.
27,
87-100[Medline]
[Order article via Infotrieve]
|
| 43.
|
Sasaoka, T.,
Langlois, W. J.,
Leitner, J. W.,
Draznin, B.,
and Olefsky, J. M.
(1994)
J. Biol. Chem.
269,
32621-32625[Abstract/Free Full Text]
|
| 44.
|
Yamauchi, K.,
and Pessin, J. E.
(1994)
J. Biol. Chem.
269,
31107-31114[Abstract/Free Full Text]
|
| 45.
|
Leevers, S. J.,
Paterson, H. F.,
and Marshall, C. J.
(1994)
Nature
369,
411-414[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Stokoe, D.,
Macdonald, S. G.,
Cadwallader, K.,
Symons, M.,
and Hancock, J. F.
(1994)
Science
264,
1463-1467 |